Cannabis Withdrawal Syndrome

Clinical Recognition and Diagnosis

• The American Psychiatric Association recognizes cannabis withdrawal syndrome as a criterion for cannabis use disorders, requiring abrupt cessation of prolonged or heavy cannabis use and three or more symptoms, including irritability, anxiety, insomnia, and physical symptoms, according to the DSM-5 1
• The diagnosis of cannabis withdrawal syndrome involves identifying symptoms such as irritability, anxiety, insomnia, decreased appetite, restlessness, altered mood, and physical symptoms, as outlined in the British Journal of Anaesthesia 1

Timeline and Natural History

• Symptom onset typically occurs within 24-72 hours of cessation, with most symptoms peaking between days 2-6, and the acute withdrawal phase generally lasting 1-2 weeks, as reported in the British Journal of Anaesthesia 1
• Cannabis craving peaks in the first week but may persist for months or even years, according to the Annals of Oncology 2, 3

Risk Factors and Severity Predictors

• Patients consuming more than 1.5 g/day of inhaled cannabis, more than 20 mg/day of THC-dominant cannabis oil, or more than 300 mg/day of CBD-dominant oil are at higher risk for cannabis withdrawal syndrome, as stated in the British Journal of Anaesthesia 1
• Patients using cannabis products with unknown THC/CBD content more than 2-3 times per day are also at increased risk, according to the British Journal of Anaesthesia 1

Clinical Significance and Complications

• The clinical importance of cannabis withdrawal lies in its role as a precipitant for relapse to cannabis use, particularly in perioperative settings, as noted in the British Journal of Anaesthesia 1
• Pain itself may be a withdrawal symptom and not simply an exacerbation of original chronic pain, with descending pain facilitatory tracts showing increased firing during early abstinence, as reported in the Mayo Clinic Proceedings 4

Management Approach

• For patients with significant cannabis withdrawal syndrome symptoms in the postoperative period who were consuming high amounts of cannabis, nabilone or nabiximols substitution is appropriate, as recommended in the British Journal of Anaesthesia 1
• Patients with suspected cannabis withdrawal syndrome should be referred to psychiatry or addiction medicine specialists who can initiate or guide treatment with nabilone or nabiximols, according to the British Journal of Anaesthesia 1

Long-Term Considerations

• Anxiety and depressive symptoms may emerge or intensify during withdrawal, and assessing for concurrent mental health disorders is crucial, as noted in the Mayo Clinic Proceedings 4
• Provide cannabis cessation counseling and consider psychological support, given that anxiety is a prominent feature of cannabis withdrawal syndrome, as reported in the Mayo Clinic Proceedings 4

Management of Cannabis Withdrawal Syndrome

Understanding the Clinical Picture

• Approximately 47% of regular cannabis users experience cannabinoid withdrawal syndrome (CWS) after cessation of heavy and prolonged use, with symptoms including anxiety, irritability, and gastrointestinal symptoms, according to the American Gastroenterological Association 5

Immediate Management Approach

• The American College of Gastroenterology recommends standard antidiarrheal agents, such as loperamide, for diarrhea and gastrointestinal distress in cannabis withdrawal syndrome 6
• The American Gastroenterological Association and American College of Gastroenterology advise avoiding opioids entirely, as they worsen nausea, carry addiction risk, and do not address the underlying pathophysiology 7
• Ondansetron may be tried for nausea in cannabis withdrawal syndrome, although efficacy is often limited, as suggested by the American College of Gastroenterology 8

Monitoring Considerations

• The American College of Gastroenterology recommends assessing for concurrent mental health disorders, such as anxiety and depression, which are common comorbidities in cannabis withdrawal syndrome 8

Long-term Relapse Prevention

• The American College of Gastroenterology suggests providing cannabis cessation counseling and considering psychological support, given anxiety is a prominent feature of cannabis withdrawal syndrome 8

Cannabis Withdrawal Syndrome

Clinical Features

• The American College of Physicians recommends recognizing that symptom onset typically begins within 24-48 hours of abstinence in patients with cannabis withdrawal syndrome 9
• The American Gastroenterological Association notes that vomiting occurs during active chronic cannabis use in patients with cannabinoid hyperemesis syndrome, with pathognomonic hot water bathing behavior present in 44-71% of cases 10
• The American Gastroenterological Association recommends that symptoms of cannabinoid hyperemesis syndrome resolve only with cannabis cessation, requiring 6+ months of abstinence for definitive resolution 10

Diagnostic Distinction

• The American Academy of Family Physicians recommends differentiating cannabis withdrawal syndrome from cannabinoid hyperemesis syndrome, as they present oppositely but can both cause vomiting, with vomiting occurring after stopping cannabis use in CWS and during active use in CHS 9, 10

Cessation of Cannabis Use and Resolution of CHS Symptoms

Symptoms and Timeline

• The American Society of Addiction Medicine notes that cannabis withdrawal syndrome symptoms, including irritability, anxiety, insomnia, decreased appetite, restlessness, and gastrointestinal symptoms, typically resolve within 14 days 11
• The American College of Gastroenterology acknowledges that symptoms of cannabis withdrawal syndrome peak between days 2-6 after stopping cannabis and the acute phase lasts 1-2 weeks 11

Management and Treatment

• The National Institute on Drug Abuse recommends providing cannabis cessation counseling and psychological support for anxiety during the cessation period 11
• The American Academy of Family Physicians suggests that standard antidiarrheal agents like loperamide can be used for GI distress during withdrawal 11

Cannabis Cessation and CHS Symptom Resolution

CHS Symptom Resolution Timeline

• The American Gastroenterological Association suggests that complete resolution of CHS symptoms requires at least 6 months of continuous cannabis abstinence, or an abstinence duration equal to at least the total duration of 3 typical vomiting cycles for that specific patient 12
• Cyclic vomiting episodes, nausea, abdominal pain, and compulsive hot water bathing behavior resolve after cannabis cessation, as reported by the Gastroenterology society 12

Management and Prevention

• The Gastroenterology society recommends tricyclic antidepressants, such as amitriptyline, as the mainstay of preventive therapy for long-term CHS prevention, starting at 25 mg at bedtime and titrating weekly to reach a minimal effective dose of 75-100 mg 12

Management of Gastrointestinal Symptoms in Cannabinoid Hyperemesis Syndrome

Acute Phase Management

• The American Gastroenterological Association recommends ruling out life-threatening conditions, including acute abdomen, bowel obstruction, mesenteric ischemia, pancreatitis, and myocardial infarction, before confirming CHS diagnosis 13
• Benzodiazepines, particularly lorazepam, are the most effective acute treatment for nausea and vomiting in CHS patients, based on multiple case series and prospective studies 13
• Haloperidol is the second-line agent for acute symptom control in CHS patients 13
• Topical capsaicin (0.1% cream) can be applied with close monitoring for efficacy and adverse effects, as it activates transient receptor potential vanilloid type 1 receptors 13
• Opioids should never be used in CHS patients as they worsen nausea, carry high addiction risk, and do not address the underlying pathophysiology 13

Diagnostic Confirmation

• The diagnostic criteria for CHS require all three of the following: stereotypical episodic vomiting occurring 3+ times annually, cannabis use >1 year before symptom onset with frequency >4 times per week, and resolution of symptoms after 6+ months of abstinence or duration equal to 3 typical vomiting cycles 13

Common Pitfalls to Avoid

• The American Gastroenterological Association recommends not pursuing exhaustive investigations once CHS is suspected, and instead focusing on making an early diagnosis to facilitate treatment 13

Long-Term Management Strategy

• The American Gastroenterological Association recommends tricyclic antidepressants, such as amitriptyline, as the mainstay of long-term preventive therapy for CHS patients, starting at 25 mg at bedtime and titrating weekly by 25 mg increments to reach the minimal effective dose of 75-100 mg 13
• Complete resolution of CHS symptoms requires at least 6 months of continuous cannabis abstinence, or abstinence duration equal to at least 3 typical vomiting cycles for that patient, and patients should be informed that symptom resolution only occurs with complete and sustained cannabis abstinence 13

Cannabinoid Hyperemesis Syndrome and Cannabis Withdrawal Syndrome

Diagnostic Approach

• The American Gastroenterological Association recommends determining whether abdominal cramps in cannabis users represent Cannabinoid Hyperemesis Syndrome (CHS) or Cannabis Withdrawal Syndrome (CWS), as they require opposite management strategies, with CHS occurring during active cannabis use and requiring cessation, and CWS occurring after stopping cannabis and may require supportive care 14
• The American Gastroenterological Association suggests that CHS is characterized by stereotypical episodic vomiting occurring ≥3 times annually with chronic daily cannabis use, cannabis use >1 year before symptom onset, frequency >4 times per week, compulsive hot water bathing behavior, and abdominal pain accompanying vomiting episodes 14
• The British Journal of Anaesthesia guidelines state that CWS occurs after stopping cannabis, with symptom onset 24-72 hours after cessation in heavy users, and is characterized by irritability, anxiety, insomnia, decreased appetite, restlessness alongside abdominal pain, and a history of consuming >1.5 g/day or using >2-3 times daily 15

Management

• The American Gastroenterological Association recommends that first-line acute treatment for CHS is parenteral benzodiazepines, specifically lorazepam, which are the most effective agents for CHS-related nausea and vomiting, and topical capsaicin 0.1% cream can be applied to activate TRPV1 receptors 14
• The American Gastroenterological Association suggests that cannabis cessation is the only definitive cure for CHS, with symptoms requiring at least 6 months of continuous abstinence or duration equal to 3 typical vomiting cycles for complete resolution, and preventive pharmacotherapy with amitriptyline starting at 25 mg at bedtime, titrating weekly by 25 mg increments to reach 75-100 mg 14
• The British Journal of Anaesthesia guidelines recommend that supportive care is the mainstay for CWS, with loperamide for diarrhea and GI distress, ondansetron may be tried for nausea, and consider gabapentin, nabilone, nabiximols, or dronabinol for significant withdrawal symptoms, and avoid opioids due to worsening nausea and addiction risk 15

Treatment for Cannabis-Induced Hyperemesis and Esophagitis

Immediate Acute Management

• The American Gastroenterological Association recommends lorazepam dosing: 0.5-2 mg every 4-6 hours during acute episodes, providing both antiemetic effects through sedation and anxiolytic properties that address the stress-mediated component of CHS, with evidence from prospective studies showing superior efficacy compared to standard antiemetics 16
• Alternative antipsychotics include promethazine (12.5-25 mg every 4-6 hours) or prochlorperazine (5-10 mg every 6-8 hours), though these are less effective than haloperidol, according to the American Gastroenterological Association 16

Management of Esophagitis

• The esophagitis in this clinical scenario is an epiphenomenon of recent retching and vomiting, not a causal factor, and should be recognized as secondary to the hyperemesis syndrome, as stated by the American Gastroenterological Association 17
• When esophagogastroduodenoscopy is performed soon after a CHS episode, findings such as mild gastritis, erythematous streaking, Mallory-Weiss tears, or esophagitis are consequences of vomiting, not primary pathology, according to the American Gastroenterological Association 17
• Repeated esophagogastroduodenoscopy should be avoided unless there are specific indications beyond the CHS diagnosis, as recommended by the American Gastroenterological Association 17

Supportive Care and Monitoring

• Basic laboratory workup should include complete blood count, serum electrolytes and glucose, liver function testing, and lipase, as recommended by the American Gastroenterological Association 17

Definitive Long-Term Management

• Complete resolution of CHS symptoms requires at least 6 months of continuous cannabis abstinence, or abstinence duration equal to at least 3 typical vomiting cycles for that specific patient, according to the American Gastroenterological Association 17
• Provide cannabis cessation counseling and consider referral to addiction medicine specialists or substance use specialists, as recommended by the American Gastroenterological Association 17
• Tricyclic antidepressants, specifically amitriptyline, are the mainstay of long-term preventive therapy for CHS patients, and can be initiated even while working toward cannabis cessation, according to the American Gastroenterological Association 17
• Cognitive behavioral therapy or mindfulness meditation may improve overall quality of life, as stated by the American Gastroenterological Association 17

Cannabinoid Hyperemesis Syndrome: Evidence‑Based Diagnosis, Treatment, and Follow‑Up

Diagnosis

• In adolescents and adults with chronic cannabis use who present with recurrent, stereotypical episodic vomiting, normal laboratory studies (including pancreatic enzymes, complete blood count, renal function, and urinalysis) and normal abdominal imaging, the diagnosis of Cannabinoid Hyperemesis Syndrome (CHS) should be made. 18
• A history of compulsive hot‑water bathing or showering for symptom relief is reported in 44–71 % of CHS cases and is a highly suggestive feature. 18
• Diagnostic cannabis‑use criteria include ≥1 year of regular consumption and ≥4 uses per week before symptom onset. 18
• The syndrome is defined by ≥3 vomiting episodes per year with an acute onset pattern. 18

Acute Management (Emergency Department)

• First‑line therapy: Intravenous or oral benzodiazepines (e.g., lorazepam 0.5–2 mg every 4–6 hours) are the most effective agents for rapid control of CHS‑related nausea and vomiting. 18
• Second‑line therapy: Antipsychotics such as haloperidol or droperidol can halve the length of hospital stay (average 6.7 h vs 13.9 h; p = 0.014). 18
• Adjunctive therapy: Topical capsaicin 0.1 % cream applied to the abdomen activates TRPV1 receptors and consistently relieves symptoms. 18
• Medications to avoid: Opioids should never be used in CHS because they exacerbate nausea, carry a high addiction risk, and do not address the underlying pathophysiology. 18

Long‑Term Management

• Definitive cure: Complete cessation of cannabis is the only curative approach; symptom resolution requires at least 6 months of continuous abstinence (or a period equivalent to three typical vomiting cycles). 18
• Ineffective strategies: Partial reduction of use or switching to edible forms does not lead to symptom improvement; full abstinence is mandatory. 18
• Recidivism risk: Relapse rates exceed 40 % in reported series, underscoring the need for ongoing support. 18
• Preventive pharmacotherapy: Tricyclic antidepressants, specifically amitriptyline, are the mainstay for long‑term prophylaxis. Initiate at 25 mg at bedtime, increase by 25 mg weekly, and target a maintenance dose of 75–100 mg at bedtime. 18
• Psychosocial care: Referral to addiction‑medicine specialists or substance‑use counselors is essential; co‑management with psychiatry is advisable given the high prevalence of anxiety and depression comorbidities. 18

Common Pitfalls

• Unnecessary investigations: Once CHS is suspected, extensive diagnostic testing should be avoided, as it leads to unnecessary procedures and an average diagnostic delay of several years. 18
• Over‑reliance on hot‑water bathing: Although present in 71 % of CHS patients, similar bathing behavior occurs in 44 % of cyclic vomiting syndrome cases; it is not exclusively pathognomonic. 18
• Opioid use for pain: Opioids worsen nausea and carry a high addiction potential in this population and should be omitted. 18
• Patient denial: Clinicians must not accept patient denial of the cannabis‑symptom link; many patients attribute vomiting to food, alcohol, or stress, which can impede appropriate counseling. 18

Prognosis and Follow‑Up

• Resolution: Complete and sustained cannabis abstinence is required for symptom resolution; partial measures are ineffective. 18
• Follow‑up: Regular outpatient follow‑up is critical to monitor for relapse, reinforce cessation strategies, and provide ongoing psychosocial support. 18

Evidence‑Based Management of Cannabis‑Related Withdrawal and Associated Risks

Withdrawal Timeline

• Symptoms of cannabis withdrawal typically begin 24–72 hours after the last use and reach their peak between days 2–6, with the acute phase lasting 1–2 weeks in most individuals【19】【20】.

Common Withdrawal Symptoms

• The withdrawal syndrome commonly includes irritability, anxiety, and insomnia【21】【19】【20】.
• Patients often experience reduced appetite and restlessness【19】【20】.
• Gastro‑intestinal complaints such as abdominal pain and diarrhea are frequent during the acute phase【19】【20】.

Pharmacologic Symptom Management

• Loperamide is recommended for diarrhea and general gastrointestinal discomfort associated with cannabis withdrawal【22】.

Structured Psychosocial Interventions

• A brief motivational intervention (single session lasting 5–30 minutes with individualized feedback) improves cessation outcomes when delivered in non‑specialized settings【22】.
• When clinicians have the capacity, structured motivational interviewing techniques should be incorporated into the brief intervention【21】.
• Patients who do not respond to brief counseling should be referred for specialized evaluation (e.g., addiction medicine or psychiatry)【22】.

Referral and Specialist Care

• Specialist referral is mandatory for severe withdrawal, co‑occurring psychiatric disorders, marked social dysfunction, or severe cannabis‑use disorder【21】【22】.

Psychiatric Comorbidities and Risk of Dependence

• Chronic cannabis use is linked to a higher incidence of depressive disorders【21】【19】【20】.
• In vulnerable individuals, cannabis use can exacerbate existing psychiatric conditions【21】【19】【20】.
• Approximately 10 % of adults with chronic cannabis use develop a cannabis‑use disorder【21】【19】【20】.
• Initiating weekly or daily cannabis consumption in early life strongly predicts future dependence【21】【19】【20】.

Mutual‑Aid and Community Support

• Clinicians should encourage participation in local mutual‑aid groups and involve family members to reinforce recovery efforts【21】.

Driving Safety

• Cannabis users have more than twice the risk of being involved in motor‑vehicle accidents compared with non‑users; clinicians should discuss this risk when counseling patients【21】【20】.

Cannabinoid Hyperemesis Syndrome – Evidence‑Based Diagnosis and Management

Diagnosis

• CHS is defined by stereotypical episodic vomiting occurring ≥ 3 times per year in the setting of chronic daily cannabis use, with compulsive hot‑water bathing used for symptom relief. 23

Diagnostic Criteria (all required)

• Cannabis exposure: ≥ 1 year of regular use (> 4 times/week) preceding symptom onset. 23
• Clinical pattern: Episodic vomiting of acute onset lasting < 1 week, occurring ≥ 3 times annually. 23
• Definitive confirmation: Complete symptom resolution after ≥ 6 months of continuous cannabis abstinence (or an equivalent period of three typical vomiting cycles for the individual). 23

Key Clinical Features

• Compulsive hot‑water bathing is reported in 44–71 % of CHS patients and is highly suggestive, although it also occurs in ≈ 44 % of cyclic vomiting syndrome cases. 23
• Daily or near‑daily cannabis use is documented in 68–97 % of confirmed CHS cases. 23

Acute (Emergency Department) Management

• First‑line pharmacotherapy: Lorazepam (0.5–2 mg IV or PO every 4–6 h) is the most effective agent for acute nausea and vomiting in CHS. 23
• Adjunctive therapy: Topical 0.1 % capsaicin cream applied to the abdomen activates TRPV1 receptors and provides consistent symptom relief. 23
• Medication to avoid: Opioids should never be used in CHS because they exacerbate nausea, carry high addiction risk, and do not address the underlying pathophysiology. 23

Definitive Long‑Term Management

• Curative approach: Complete and sustained cessation of cannabis is the only definitive cure for CHS. Minimum abstinence duration is at least 6 months (or three typical vomiting cycles). 23

Preventive Pharmacotherapy

• Tricyclic antidepressant: Amitriptyline is the mainstay of long‑term preventive therapy. Initiate at 25 mg at bedtime, increase by 25 mg weekly, targeting a maintenance dose of 75–100 mg at bedtime. 23

Psychosocial Interventions

• Cannabis cessation counseling is mandatory for all patients with CHS. 23
• Referral to addiction‑medicine specialists or substance‑use counselors is essential to support sustained abstinence. 23

Common Pitfalls to Avoid

• Unnecessary investigations: Once CHS is suspected, extensive diagnostic testing should be avoided to prevent delays in appropriate management. 23
• Over‑reliance on hot‑water bathing as pathognomonic: Although present in up to 71 % of CHS patients, similar behavior occurs in ≈ 44 % of cyclic vomiting syndrome cases, limiting its diagnostic specificity. 23
• Opioid prescription for abdominal pain: Opioids worsen nausea and increase addiction potential in CHS patients. 23

Cannabis Withdrawal Syndrome: Evidence‑Based Clinical Guidance

Clinical Presentation

• Daily long‑term cannabis users develop a non‑fatal withdrawal syndrome that includes irritability, anxiety, insomnia, appetite disturbance, and abdominal pain; symptoms typically begin 24–72 hours after cessation and last 1–2 weeks, requiring primarily psychological support and symptomatic care. [24] [25]

• The onset of withdrawal symptoms occurs within 24–72 hours after the last cannabis use. [24] [26]

• Symptom intensity peaks between days 2 and 6 after cessation. 26

• The acute phase of withdrawal generally persists for 1–2 weeks, with some symptoms lasting up to 3 weeks in heavy users. [24] [25]

Psychological Symptoms (most frequent)

• Irritability, anger, or aggression are among the most common psychological manifestations of cannabis withdrawal. [24] [27] 25
• Anxiety and nervousness are frequently reported during withdrawal. [24] [27] 25
• Insomnia and other sleep disturbances, often accompanied by vivid dreams, are typical. [24] [27] 25
• Agitation and heightened nervousness are also observed. [24] [27] 25

Physical Symptoms

• Decreased appetite and consequent weight loss are common physical signs. [24] [25]
• Abdominal pain frequently accompanies other withdrawal symptoms. [24] [25]
• Headaches are reported in a subset of patients. [27] [28]
• Chills and sweating may occur during the early withdrawal period. 26

Risk Factors for Severe Withdrawal

• Individuals consuming large quantities of cannabis (e.g., high‑dose inhaled or oral preparations) are at higher risk for a clinically significant withdrawal syndrome. 26

Differentiation from Cannabinoid Hyperemesis Syndrome (CHS)

• Cannabis Withdrawal Syndrome (CWS) manifests after cessation of use, with symptom onset 24–72 hours later. 26
• Cannabinoid Hyperemesis Syndrome occurs during active, frequent cannabis use (≥4 times/week for >1 year). 24
• A characteristic compulsive behavior of hot‑water bathing or showering is reported in 44–71 % of CHS cases. 24
• The only curative treatment for CHS is complete abstinence from cannabis. 24

Pharmacologic Management of Withdrawal

• Ondansetron may be trialed for nausea, although its efficacy is often limited. 26
• Opioids should be avoided because they can exacerbate nausea and carry a high risk of dependence. 26
• Cannabinoid agonist substitution (e.g., nabilone or nabiximols) can be considered for patients with severe withdrawal, especially in postoperative or other high‑risk clinical contexts. 26

Indications for Hospital Admission

• Hospitalization for medically assisted withdrawal is indicated for patients with significant comorbid mental‑health disorders. 24
• Patients using multiple substances concurrently may also require inpatient care to prevent serious complications. 24

Referral Recommendations

• Referral to a specialist (addiction medicine or psychiatry) is mandatory for:
  
  • Severe cannabis withdrawal. 25
  • Co‑occurring psychiatric disorders. 24
  • Lack of response to brief counseling interventions. 24

Psychiatric and Long‑Term Risks

• Chronic cannabis use is linked to long‑term psychiatric risks that correlate with cumulative exposure and earlier age of initiation. [24] [25]
• Approximately 10 % of adults with chronic cannabis use develop a cannabis use disorder. [24] [25]

Safety Considerations

• Cannabis users have more than double the risk of motor‑vehicle accidents compared with non‑users; this risk should be addressed during counseling. 25

Neurobiological Recovery

• Regular cannabis consumption leads to down‑regulation of cortical and subcortical CB1 receptors; reversal of this down‑regulation begins within the first 48 hours of abstinence. 26
• CB1 receptor function typically normalizes by four weeks of sustained abstinence. 26

Clinical Implications

• Withdrawal symptoms can precipitate relapse to cannabis use, particularly in peri‑operative settings. 26

• Patients with comorbid mental‑health conditions and polysubstance use are at heightened risk for complicated withdrawal courses. 26

Guideline Summary for Acute Management of Cannabinoid Hyperemesis Syndrome

Acute Pharmacologic Management

• Lorazepam (0.5–2 mg IV or PO every 4–6 hours) is the most effective first‑line agent for acute CHS‑related nausea and vomiting. Evidence from multiple prospective studies and case series shows superior efficacy compared with conventional antiemetics. 29
• Droperidol (or haloperidol) is the preferred second‑line antipsychotic when benzodiazepines are insufficient or contraindicated, reducing hospital length of stay by roughly 50 % (6.7 h vs 13.9 h; p = 0.014). This reduction is statistically significant and reflects a clinically meaningful shortening of admission time. 29

Mechanism of Action

• Droperidol’s dopamine D₂‑receptor antagonism in the chemoreceptor trigger zone, combined with its sedating properties, targets both the neurochemical and stress‑mediated pathways that drive vomiting in CHS. 29

Adjunctive Therapies

• Topical capsaicin 0.1 % cream applied to the abdomen provides consistent symptom relief by activating TRPV1 receptors. 29

Medications to Avoid

• Opioids should never be used in CHS patients because they worsen nausea, carry a high risk of addiction, and do not address the underlying pathophysiology. 29
• 5‑HT₃ antagonists such as ondansetron have limited efficacy in CHS and should not be relied upon as primary therapy. 29

Long‑Term Management

• Sustained cannabis cessation for at least 6 months (or a duration equal to three typical vomiting cycles) is the only curative treatment for CHS. Partial reduction or switching to edible forms does not improve symptoms. 29
• Amitriptyline is recommended for prophylaxis: start 25 mg at bedtime, increase by 25 mg weekly, and target a maintenance dose of 75–100 mg at bedtime. Tricyclic antidepressants are the mainstay of long‑term prevention. 29

Diagnostic Confirmation

These three criteria together confirm CHS. 29

• Hot‑water bathing behavior occurs in 44–71 % of CHS cases but also in ~44 % of cyclic vomiting syndrome patients, limiting its diagnostic specificity. 29

Common Pitfalls

• Extensive diagnostic testing after CHS is suspected leads to unnecessary procedures and delays that can average several years; early diagnosis shortens this interval. 29
• Patients often deny the link between cannabis use and vomiting, which hampers counseling and appropriate management. (no citation needed)
• Referral to addiction‑medicine specialists or substance‑use counselors is essential because relapse rates exceed 40 %; co‑management with psychiatry is advisable given the high prevalence of anxiety and depression comorbidities. 29

Haloperidol Use in Cannabinoid Hyperemesis Syndrome – Evidence‑Based Recommendations

Safety Monitoring

• Obtain a baseline electrocardiogram before administering haloperidol to patients with known cardiac risk factors or electrolyte disturbances, to identify QT‑c prolongation risk. 30

Contraindications

• Opioid analgesics should be avoided in CHS because they exacerbate nausea, carry a high addiction potential, and do not address the underlying pathophysiology. [30][31]

Adjunctive Therapies to Combine with Haloperidol

• Initiate intravenous fluids containing dextrose for all CHS patients presenting to the emergency department to correct dehydration and support metabolic needs. 31
• Use intravenous ketorolac as the preferred non‑opioid analgesic for severe abdominal pain in CHS, providing effective pain control without narcotic‑related worsening of symptoms. 31
• Provide a quiet, dimly lit environment for patients receiving haloperidol, as reduced sensory stimulation enhances the drug’s sedating and anti‑emetic effects. 31

Clinical Practice Recommendations

• Reserve haloperidol for acute rescue therapy within the emergency department; it should not be prescribed for outpatient maintenance because evidence supports its use only as a short‑term, second‑line anti‑emetic. [30][31]
• Prior to attributing vomiting to CHS, systematically exclude life‑threatening conditions such as acute abdomen, bowel obstruction, mesenteric ischemia, pancreatitis, and myocardial infarction. This safety step is emphasized in the guideline. 31